The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitis

Current Opinion in Rheumatology

Volumn 20, Issue 4, 2008, Pages 384-391

  Brionez, Tamar F ^a   Reveille, John D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Ankylosing spondylitis; ARTS1; Genetics; IL23R; Interleukin 1

Indexed keywords

ALKALINE PHOSPHATASE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOCHROME P450; CYTOCHROME P450 2D6; HLA B27 ANTIGEN; INTERLEUKIN 1ALPHA; INTERLEUKIN 23 RECEPTOR; TISSUE NONSPECIFIC ALKALINE PHOSPHATASE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; AMINOPEPTIDASE; ARTS 1 PROTEIN, HUMAN; ARTS-1 PROTEIN, HUMAN; IL23R PROTEIN, HUMAN; INTERLEUKIN RECEPTOR;

ANKH GENE; ANKYLOSING SPONDYLITIS; ARTS1 GENE; CHROMOSOME 10; CHROMOSOME 16Q; CHROMOSOME 19Q; CHROMOSOME 3; GENE; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; RETROSPECTIVE STUDY;

AMINOPEPTIDASES; GENETIC PREDISPOSITION TO DISEASE; HLA-B27 ANTIGEN; HUMANS; INTERLEUKIN-1ALPHA; MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTORS, INTERLEUKIN; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING;

EID: 47049088631     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32830460fe     Document Type: Review

References (66)

1. Brown MA, Pile KD, Kennedy LG, et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996; 55:268-270.
2. Reveille JD. Major histocompatibility genes and ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006; 20:601-609.
3. van der Linden SM, Valkenburg HA, de Jongh BM, et al. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984; 27:241-249.
4. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985; 44:359-367.
5. Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997; 40:1823-1828.
6. Breban M. Genetics of spondyloarthritis. Best Pract Res Clin Rheumatol 2006; 20:593-599.
7. Brown MA, Laval SH, Brophy S, et al. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000; 59:883-886.
8. Carter KW, Pluzhnikov A, Timms AE, et al. Combined analysis of three whole genome linkage scans for ankylosing spondylitis. Rheumatology 2007; 46:763-771. A meta-analysis of the three published genome linkage scans confirming a strong linkage at chromosome 16q and moderate linkage at sites on chromosomes 3, 10 and 19q. Probably the most comprehensive and well powered look at this methodology to date.
9. Brophy S, Hickey S, Menon A, et al. Concordance of disease severity among family members with ankylosing spondylitis? J Rheumatol 2004; 31:1775-1778.
10. Hamersma J, Cardon LR, Bradbury L, et al. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum 2001; 44:1396-1400.
11. Brown MA, Pile KD, Kennedy GL, et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum 1998; 41:588-595.
12. Laval SH, Timms A, Edwards S, et al. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet 2001; 68:918-926.
13. Zhang Ge, Luo J, Bruckel J, et al. Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis Rheum 2004; 50:2246-2254.
14. Miceli-Richard C, Zouali H, Said-Nahal R, et al. Significant linkage to spondyloarthropathy on 9q31-34. Hum Mol Genet 2004; 13:1641-1648.
15. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-683. A large genome-wide association study evaluating seven common diseases validating the genome-wide association approach using SNP chips.
16. Wellcome Trust Case Control Consortium and The Australo-Anglo-American Spondylitis Consortium. Nat Genet 2007; 39:1329-1336. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. The same methodology above applied to AS, multiple sclerosis, and autommine thyroid disease. Of particular note was the identification of two novel genetic factors (IL23R and ARTS) in the UK cohort that was confirmed in a separate North-American cohort.
17. Reveille JD. The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol 2006; 18:332-341.
18. Beyeler C, Armstrong M, Bird HA, et al. Relationship between genotype for the cytochrome p450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1996; 55:66-68.
19. Brown MA, Edwards S, Hoyle E, et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet 2000; 9:1563-1566.
20. Kim TH, Rahman P, Jun JB, et al. Analysis of CARD15 polymorphisms in Korean patients with ankylosing spondylitis reveals absence of common variants seen in Western populations. J Rheumatol 2004; 31:1959-1961.
21. Van der Paardt M, Crusius JBA, de Koning MHMT, et al. CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun 2003; 4:77-78.
22. D' Amato M, Sorrentino R, Pettersson S. The Crohn's associated NOD2 3020InsC frameshift mutation does not confer susceptibility to ankylosing spondylitis [letter to the editor]. J Rheumatol 2002; 29:2470-2471.
23. Ferreiros-Vidal I, Amarelo J, Barros F, et al. Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. J Rheumatol 2003; 30:102-104.
24. Jaakkola E, Crane AM, Laiho K, et al. The effect of transforming growth factor beta1 gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford) 2004; 43:32-38.
25. van der Paardt M, Crusius JB, Garcia-Gonzalez MA, et al. Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor beta 1 (TGFB1) gene polymorphisms. Ann Rheum Dis 2005; 64:616-619.
26. Howe HS, Cheung PL, Kong Ko, et al. Transforming growth factor beta-1 and gene polymorphisms in oriental ankylosing spondylitis. Rheumatology (Oxford) 2005; 44:51-54.
27. Tsui FWL, Tsui HW, Cheng EY, et al. Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 2003; 48:791-797.
28. Tsui HW, Inman RD, Paterson AD, et al. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 2005; 7:R513-R525.
29. Timms AE, Zhang Y, Bradbury L, et al. Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 2003; 48:2898-2902.
30. Tsui HW, Inman RD, Reveille JD, et al. Association of a TNAP haplotype with ankylosing spondylitis. Arthritis Rheum 2007; 56:234-243. Through analysis of six SNPs in the TNAP gene, a haplotype association with AS was reported. This needs to be confirmed in another cohort.
31. van der Paardt M, Crusius JBA, de Koning MHMT, et al. No evidence for involvement of the toll-like receptor 4 (TLR4) A896G and CD14-C260T polymorphisms in susceptibility to ankylosing spondylitis. Ann Rheum Dis 2005; 64:235-238.
32. Gergely P, Blazsek A, Weiszhar Z, et al. Lack of genetic association of the toll-like receptor 4 (TLR4) Asp299Gly and Thr399Ile polymorphisms with spondyloarthropathies in a Hungarian population. Rheumatology 2006; 45:1194-1196.
33. Adam R, Sturrock RD, Gracie JA. TLR4 mutations (Asp299Gly and Thr399Ile) are not associated with ankylosing spondylitis. Ann Rheum Dis 2006; 65:1099-1101.
34. Snelgrove T, Lim S, Greenwood C, et al. Association of toll-like receptor 4 variants and ankylosing spondylitis: a case-control study. J Rheumatol 2007; 34:368-370. A modest association was demonstrated between the GT haplotype (Asp299Gly and Ther399Ile variants) and AS in a Newfoundland population.
35. Brown MA. Nonmajor-histocompatibility-complex genetics of ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006; 20:611-621.
36. Jacques C, Gosset M, Berenbaum F, et al. The role of IL1 and IL1-Ra in joint inflammation and cartilage degradation. Vitam Horm 2006; 74:371-403.
37. Yasuo N, Harumoto Y, Toshiyuki K, et al. Membrane- associated IL1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transgenic mice. J Immunol 2004; 172:577-584.
38. van der loo FA, Joosten LA, van Lent PL, et al. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38:164-172.
39. Collotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993; 261:472-475.
40. Djouadi K, Nedelec B, Tamouza R, et al. Interleukin 1 gene cluster polymorphisms in multiplex families with spondyloarthropathies. Cytokine 2001; 13:98-103.
41. Li J, Ge Z, Akey JM, et al. Lack of linkage of IL1RN genotypes with ankylosing spondylitis susceptibility. Arthritis Rheum 2004; 50:3047-3048.
42. Timms AE, Crane AM, Sims AM, et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am JHum Genet 2004; 75:587-595.
43. Kim T, Stone MA, Rahman P, et al. Interleukin 1 and nuclear factor-KB polymorphisms in ankylosing spondylitis in Canada and Korea. J Rheumatol 2005; 32:1907-1910.
44. Maksymowych WP, Rahman P, Reeve JP, et al. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum 2006; 54:974-985.
45. McGarry F, Neilly J, Anderson N, et al. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology 2001; 40:1359-1364.
46. van der Paardt M, Crusius JBA, Garcia-Gonzalez MA, et al. Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. Rheumatology 2002; 41:1419-1423.
47. Wu Z, Gu JR. A meta-analysis on interleukin-1 gene cluster polymorphism and genetic susceptibility for ankylosing spondylitis. Zhonghua Yi Xue Za Zhi 2007; 87:433-437; Original article in Chinese.
48. Jin L, Weisman MA, Zhang G, et al. Lack of association and linkage of IL1RN genotypes with ankylosing spondylitis susceptibility. Arthritis Rheum 2004; 50:3047-3048.
49. Maksymowych WP, Reeve JP, Reveille JD, et al. High-throughput single-nucleotide polymorphism analysis of the ILRN locus in patients with anky-losing spondylitis by matrix-assisted laser desorption ionization-time-of- flight mass spectometry. Arthritis Rheum 2003; 48:2011-2018.
50. Chou CT, Timms AE, Wei JCC, et al. Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Ann Rheum Dis 2006; 65:1106-1109.
51. Sims AM, Timms AE, Bruges-Armas J et al. Prospective meta-analysis of IL-1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis (in press). This is a meta-analysis of studies done by the International Genetics of AS Consortium on IL-1 region genes and AS. The strong association with three SNPs in the IL-1A gene (as opposed to IL-1B and IL-1RN) and AS was identified here.
52. Cui X, Rouhani F, Hawari F, et al. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J Biol Chem 2003; 278:28677-28685.
53. Firat E, Saveanu L, Aichele P, et al. The role of endoplasmic reticulum- associated aminopeptidase 1 in immunity to infection and in cross-presentation. J Immun 2007; 178:2241-2248.
54. Yan J, Parekh V, Mendez-Fernandez Y, et al. In vivo role of ER- associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med 2006; 203:647-659.
55. Hammer GE, Kanaseki T, Shastri N. The final touches make perfect the peptide-MHC class I repertoire. Immunity 2007; 26:397-406.
56. Cui X, Hawari F, Alsaaty S, et al. Identification of ARTS-1 as a novel TNFR1 binding protein that promotes TNFR1 ectodomain shedding. J Clin Invest 2002; 110:515-526.
57. Cui X, Rouhani FN, Hawari F, et al. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase: aminopeptidase regulator of TNF receptor type I shedding. J Immunol 2003; 171:6814-6819.
58. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461-1463.
59. Tremelling M, Cummings F, Fisher SA, et al. Il23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 2007; 132:1657-1664.
60. Buning C, Schmidt HJ, Molnar T, et al. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment Pharmacol Ther 2007; 26:1025-1033.
61. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80:273-390.
62. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116:1218-1222.
63. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191.
64. Brand S, Staudinger T, Schnitzler F, et al. The role of toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005; 11:645-652.
65. Browning BL, Huebner C, Petermann I, et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 2007; 102:2504-2512.
66. Torok HP, Glas J, Tonenchi L, et al. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 112:85-91.